Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.2828 | 0.4946 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.235 | 0.2852 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.3981 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.235 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3914 | 0.9706 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.235 | 0.2852 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3914 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.3914 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.235 | 0.2852 | 0.5 |
Onchocerca volvulus | 0.3981 | 1 | 0.5 | |
Giardia lamblia | Hypothetical protein | 0.235 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3981 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3914 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.3981 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2828 | 0.4946 | 0.321 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.3914 | 0.9706 | 0.9706 |
Schistosoma mansoni | 6-phosphofructokinase | 0.3981 | 1 | 1 |
Loa Loa (eye worm) | TKL/MLK/LZK protein kinase | 0.2828 | 0.4946 | 0.321 |
Loa Loa (eye worm) | hypothetical protein | 0.2828 | 0.4946 | 0.321 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.